Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market Is Expected To At A CAGR 9.8% During The Forecast Period 2017 – 2025

Product Summary

The study is given to the analysis of the latest growth trends and prospects for the Acute Bacterial Skin And Skin Structure Infections market.

The section „Acute Bacterial Skin And Skin Structure Infections Market“ includes an examination of the situation in major sections of the Acute Bacterial Skin And Skin Structure Infections market. The markets in European Union countries are examined in more detail, giving a timeline of financial results reported by major 3PL providers in 2017.

Browse full report: https://www.credenceresearch.com/report/acute-skin-and-skin-structure-bacterial-infection-abssi-treatment-market

Market Insight:

According to USFDA, acute bacterial skin and skin structure infections, or ABSSSI—includes the following criteria: accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ≥38°C (100.4°F). The symptoms observed in ABSSSI are extensive cellulitis, wound infection, major cutaneous abscesses, and burn infections. ABSSSI is mainly caused due to Methicillin-susceptible Staphylococcus aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumonia and Klebsiella oxytoca. According to research reports in the United States, average inpatient costs per ABSSSI patient ranges between US$6,000 to US$13,000 recorded in 2016, with multi-day room and board expenses comprising 50% of total costs. The market experts suggested that, most of the ABSSSI patients are frequently admitted to the hospital only for the administration of intravenous antibiotics.

The ABSSSI treatment market is segmented on the basis of drug type, infection type and pathogen type. In year 2016, vancomycin was observed as the leading segment in terms of revenue globally in treatment of ABSSSI due to key drivers such as most preferred molecule against multiple drug resistant bacterial infections, and certainly it has lost exclusivity which makes it affordable. However, during forecast period 2017 – 2025, delafloxacin is expected to grow at a significant rate due to key drivers such as its exclusive approval against ABSSI and high efficiency compared to existing drugs.

There are several types of ABSSSIs such as cellulitis, abscess/boil/cyst, surgical wound, and traumatic wound. In year 2016, cellulitis was observed as the largest segment due to key driving factors such as increasing prevalence of multiple drug resistant bacterial infections, mounting hospitalization of patients with chronic diseases due to high medical awareness, increasing prevalence of hospital-acquired infections, and continuous R&D activities observed in ABSSSI treatment industry.

There are several pathogens that lead to ABSSSIs such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and others. In year 2016, MRSA & MSSA were observed as the largest segments and accounted for more than 50% of the total market share due to key drivers such as rising prevalence of multi-resistance bacterial infections, high public awareness associated with hospital acquired infections, and incessant research and development in field of ABSSSI treatment. According to American Pharmacists Association, approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult.

Market Competition Assessment:

The acute bacterial skin and skin structure infections market is observed as the most diversified and competitive market comprising large number of players.  The market is dominated by several players, depending on their major competencies. The key players in this market are Furiex Pharmaceuticals, Inc., GlaxoSmithKline plc, Melinta Therapeutics, Inc, Debiopharm International S.A., MerLion Pharmaceuticals Pte Ltd., Durata Therapeutics, Inc., Paratek Pharmaceuticals, Inc. and Cempra, Inc. among others.

“Acute Bacterial Skin And Skin Structure Infections Market” is a new report by us that explains how companies‘ acquisition expenditures, media spend, business strategies, marketing and sales strategies and practices, and business plan are set to change in 2017-2018. This paper gives you access to the category-level spending forecasts, business challenges, budgets, supplier selection criteria, the current size of the marketing and promotion budgets and investment opportunities for senior-level officials. The report also identifies the expected growth of buyers and suppliers, capital expenditure, staff hiring, M and A, and e-procurement. This report not only gives access to the views and strategies of business decision makers and rivals but also examines their actions circling business priorities. The report also provides access to information categorized by company type and sizes, region,

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from Our Research’s elite panel of leading global senior level executives from enterprises such as such as medical devices, mining, packaging, power, oil, and gas, food and beverage, airports and pharmaceutical. The report covers key topics such as appropriation behaviors and strategies, the current size of the marketing and advertising budgets. Besides the report also recognizes the threats and possibilities, economic outlook trends, media channel spending outlooks, M and A expectations, marketing agency selection models, media budgets, business challenges and confidence among senior-level executives across various industries. Most secondary research papers are based on general industry drivers and do not understand the industry officials‘ attitude and changing behaviors, creating a gap in showing the business opportunity of the industry. In an effort to bridge this gap, Our Research created this primary-research based report by selecting the opinions of various stakeholders in the value-chain of the industry

This report offers:

  • Analysis of several products, and regions that would provide the clear understanding of the ongoing and future trends in the global Acute Bacterial Skin And Skin Structure Infections market
  • Assessment of market dynamics such as drivers, restraints, and opportunities prevalent in the market
  • Quantitative assessment of the current market size and future estimations for the period from 2016 to 2026, along with CAGRs for the period from 2018 to 2026
  • Company profiles that will highlight key information about the imperative players operating in the global Acute Bacterial Skin And Skin Structure Infections devices market

Here you can get an updated sample on this report: https://www.credenceresearch.com/sample-request/58628

About us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in the Asia Pacific and 12% in the Middle East and Africa.

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

Contact Us:

Credence Research Inc.

105 N 1st ST #429

SAN JOSE

CA 95103

United States

Email:

sales@credenceresearch.com

http://www.credenceresearch.com